Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteaislingcapital.com
Phone212 651 6380
Emailjhoerrner@aisling...
Employees

Funds

Offices

New York, USA
888 Seventh Avenue
30th Floor
New York, NY, 10106
USA

People

Managing Partner
Managing Partner
Partner
Partner
Partner
Partner
Senior Managing Partner
Managing Director
Show All People

Tags

Aisling Capital

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Recent Milestones

Investments

Company Date Round Size Participants
Versartis 2/2014Series E$55M4
Miramar Labs 2/2014Series D$10M5
ViewRay 12/2013Venture Round$30M5
Versartis 10/2013Series D$20M6
Loxo Oncology 10/2013Series A$33M2
LensAR 10/2013Debt$60M3
Versartis 7/2013Series C$12.5M4
TRIA Beauty 7/2013Private Equity$45.5M7
ViewRay 5/2013Series D$15M5
Esperion Therapeutics 4/2013Venture Round$33M7
T2 Biosystems 3/2013Series E$40M10
Versartis 1/2013Series C$25M4
Ambit Biosciences 11/2012Venture Round$50M9
Aragon Pharmaceuticals 10/2012Series D$50M4
TRIA Beauty 10/2012Venture Round$7.5M4
Agile Therapeutics 7/2012Series C$40M6
ViewRay 3/2012Series C$45M5
LensAR 3/2012Venture Round$24M2
CeNeRx BioPharma 2/2012Series D$4.6M3
Roka Bioscience 1/2012Series D$47.5M4
ViewRay 9/2011Venture Round$10M5
T2 Biosystems 8/2011Series D$23M10
TRIA Beauty 2/2011Venture Round$26.3M4
NextWave Pharmaceuticals 1/2011Series C$45M7
ViewRay 8/2010Series C$20M5
Zeltiq Aesthetics 6/2010Series D$25M4
Aragon Pharmaceuticals 4/2010Series B$22M3
TransEnterix 1/2010Series B$55M6
Xanodyne 10/2009Series D$87.8M7
Cempra 6/2009Series C$46M6
Esperion Therapeutics 5/2008Series A$22.8M4
BioRelix 6/2007Series A$25.8M6
Bioenvision 4/2007Venture Round$7.41M3

Videos

Sources

  1. Versartis Completes $55M Series E Financing (finsmes.com) [edit]
  2. Miramar Labs Raises $10M in Series D Funding (finsmes.com) [edit]
  3. ViewRay Secures $30M (finsmes.com) [edit]
  4. Versartis Completes $20M Series D Financing (finsmes.com) [edit]
  5. Loxo Oncology Completes $33M Series A Financing Round (finsmes.com) [edit]
  6. PDL BioPharma, Inc. (PDLI) Injects $60 Million Into LensAR, Inc., LensAR Nets a Total of $87 Million in Financing (biospace.com) [edit]
  7. SEC (sec.gov) [edit]
  8. Tria Beauty Closes $90.5M Equity-Debt Round for Cosmetic Laser Devices (pevc.dowjones.com) [edit]
  9. ViewRay Raises Fresh $15M for Its Medical Imaging Technology (pehub.com) [edit]
  10. Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials (businesswire.com) [edit]
  11. T2 Bio Takes In $40M Series E for Clinical Studies and Launch of First Diagnostic (pevc.dowjones.com) [edit]
  12. Versartis pockets $25M C round as it looks to PhII growth hormone study (fiercebiotech.com) [edit]
  13. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia (phx.corporate-ir.net) [edit]
  14. Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers (prnewswire.com) [edit]
  15. VC funding: Q4 2012 [edit]
  16. Agile Therapeutics Closes $40M Series C Financing (finsmes.com) [edit]
  17. ViewRay Closes $45M Series C Venture Capital Financing (finsmes.com) [edit]
  18. LensAR Raises $24 Million in Private Financing to Support Commercial Launch of LensAR Laser System (lensar.com) [edit]
  19. CeNeRx BioPharma, Inc.: Series D $4.6M (onbiovc.com) [edit]
  20. Roka Bioscience Secures $47.5 Million in Series D Financing (prnewswire.com) [edit]
  21. MRI-guided radiotherapy firm ViewRay gets $10M in new funding (wraltechwire.com) [edit]
  22. T2 Biosystems closes $23M Series D financing (masshightech.com) [edit]
  23. SEC (sec.gov) [edit]
  24. NextWave Pharmaceuticals Raises $45m in a Series C Financing (finsmes.com) [edit]
  25. ViewRay Secures Series C Financing (viewray.com) [edit]
  26. AltAssets (altassets.com) [edit]
  27. Aragon Pharma readies first cancer trial after $22M B round (fiercebiotech.com) [edit]
  28. TransEnterix, Inc.: Series B $55M (onbiovc.com) [edit]
  29. SEC D/A (sec.gov) [edit]
  30. Cempra Pharmaceuticals, Inc.: Series C $46M (onbiovc.com) [edit]
  31. Esperion Therapeutics Completes $22.75M Series A Financing (esperion.com) [edit]
  32. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
  33. EDGAR [edit]
Edit This Page
Last Edited 3/19/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy